

## Review Article

## Zika Virus: A Literature Review

**Dr. Soumya Kaup**Assistant Professor, Department of Microbiology, Shridevi Institute of Medical Sciences & Research Hospital,  
Tumakuru, Karnataka.**\*Corresponding author**

Dr. Soumya Kaup

Email: [drksoumya@yahoo.in](mailto:drksoumya@yahoo.in)

**Abstract:** Zika virus is a mosquito-borne arbovirus first isolated in the Zika forest in 1947. After a period of obscurity, it emerged in 2007 with an outbreak in the Yap Island, Federated States of Micronesia followed by another outbreak in 2013 in French Polynesia. During the French Polynesian outbreak, Zika virus was found to be associated with neurological complications like Guillain-Barre Syndrome. The current epidemic in Brazil also demonstrated an increased incidence of congenital malformations and neurological complications forcing the World Health Organization to declare Zika fever as a Public Health Emergency of International Concern (PHEIC). This review attempts to compile the current knowledge available on the virology, clinical features, complications, diagnosis, treatment and control of Zika virus infection.

**Keywords:** Zika virus, Arbovirus, Flavivirus, Guillain-Barre Syndrome, Microcephaly, *Aedes aegypti*

---

### INTRODUCTION

Zika virus, an emerging arthropod borne virus, was first isolated incidentally from the serum of a sentinel febrile rhesus monkey which was held captive on wooden platforms in the canopy of forested areas in April 1947, in a study originally planned to recover Yellow Fever virus in the Zika forest of Entebbe area in Uganda. It is named after the Zika forest. Subsequently in January 1948, the virus was isolated from a batch of *Aedes africanus* mosquitoes raising the suspicion of the probable role of *Aedes africanus* mosquito in the transmission of Zika virus [1].

The evidence for human infection with Zika virus was put forth by Smithburn *et al.*, when they demonstrated neutralizing antibodies to Zika virus in the sera of humans from East Africa in 1952 [2]. The virus was first isolated from a human case in 1952 by Macnamara when he was investigating an outbreak of suspected Yellow Fever in Eastern Nigeria [3].

Subsequently the virus remained relatively quiescent for more than half a century with only a few sporadic cases documented [4]. During this period serological evidence of human infection have been demonstrated from various African countries and also from parts of Asia including Malaysia, the Philippines, Thailand, Vietnam, Indonesia and others [5].

Zika virus came to limelight in April 2007 when the first documented outbreak of Zika fever occurred in Yap Island, Federated States of Micronesia in Southwestern Pacific Ocean infecting approximately three quarters of Yap residents with more than 900 cases of illness attributed to Zika virus [4]. This outbreak indicated that Zika virus was an emerging viral disease with epidemic potential.

In October 2013, it emerged again with an outbreak in French Polynesia, South Pacific and this was dubbed as the biggest outbreak till then, with an estimated 28,000 Zika virus infections affecting 11% of the population and 396 laboratory confirmed cases [6-8]. This was followed by outbreaks in the Pacific Islands of New Caledonia, Cook Island and first identified in America in Easter Island [9, 10]. The first autochthonous case of Zika fever in Brazil was reported in May 2015 [11].

Zika fever was considered a mild self-limiting viral infection until increasing incidence of neurological complications like Guillain-Barre Syndrome (GBS) and congenital malformations in infants of infected pregnant women were reported in French Polynesia and America [12].

As of 20<sup>th</sup> July 2016, 65 countries and territories have reported mosquito borne transmission of

Zika virus with 13 countries and territories reporting microcephaly and other CNS malformations potentially associated with congenital Zika virus infection and 15 countries and territories reporting increased incidence of Guillain-Barre Syndrome [13].

Based on the advice of the Emergency Committee of the International Health Regulations, the Director General of World Health Organization declared, on 1<sup>st</sup> of February 2016, that the reported increase in microcephaly and other neurological disorders associated with Zika fever was a Public Health Emergency of International Concern (PHEIC) [14].

### VIROLOGY

Zika virus virion is an enveloped, icosahedral particle with a single stranded, non-segmented, positive sense Ribonucleic Acid (RNA) genome belonging to the family *Flaviviridae*, genus *Flavivirus* and is a member of the Spondweni virus group, closely related to Dengue virus [15-19]. Zika virus RNA is 10794kb in length with two flanking non-coding regions (5' and 3' NCR) and a single long open reading frame consisting of a capsid (C), precursor of membrane (prM), envelope (E) and seven non-structural proteins (NS) [20]. Zika virus strains belong to two clades: African and Asiatic, with a nucleotide divergence of less than 11.7%. The African clade consists of the MR766 prototype cluster and the Nigerian cluster. The Asiatic clade is comprised of the Micronesian strains and the Malaysian strains [18]. Studies on Zika virus genome sequences sampled in Americas and Brazil show that both have a common ancestor belonging to the Asian lineage and shows 99% identity with a sequence of Zika virus isolated from French Polynesia and that the virus spread from Brazil to the rest of the Americas [21, 22].

Similar to other mosquito-borne flaviviruses, it is believed that Zika virus infection is initiated by multiplication in dendritic cells near the site of inoculation followed by spread to lymph nodes and blood stream [5]. It has been shown that, the initial target cells after inoculation are the skin fibroblasts, epidermal keratinocytes and dendritic cells. Similar to Dengue virus, infection of epidermal keratinocytes by Zika virus induces apoptosis which helps the virus to divert antiviral immune responses by increasing their dissemination from dying cells [23].

The virus has been found to have a high mutation rate of 12 to 25 mutations a year which is equivalent to 0.12% to 0.25% of RNA mutating each year [24]. Its genome has undergone several recombination events over the years in the envelope (E) and the NS5 sequences. In addition, loss of N-linked glycosylation site in the E protein have been detected which could be related to mosquito cell infectivity and

may enable greater adaptation to *Aedes* mosquitoes [20].

### EPIDEMIOLOGY

Zika virus is an arbovirus transmitted by the bite of female mosquitoes of the genus *Aedes*. The natural transmission of Zika virus is maintained between the *Aedes* mosquito and monkeys in the sylvatic cycle, man being occasionally involved in the urban cycle [25, 26]. The virus has been demonstrated in old-world non-human primates like African Green Monkey, Red-tailed monkey, etc. which are the possible natural Zika virus reservoirs [18].

*Aedes africanus* is considered as the major vector in the sylvatic cycle and *Aedes aegypti* and potentially *Aedes albopictus* are the vectors in the human cycle of Zika virus transmission [27-29]. In addition the virus has been isolated from various mosquitoes of *Aedes* species like *Aedes apicoargenteus*, *Aedes luteocephalus*, *Aedes vittatus*, *Aedes furcifer*, *Aedes hensilii*, *Aedes dalzieli*, *Aedes apok*, *Aedes jamoti*, *Aedes flavicolis*, *Aedes grahamii*, *Aedes taeniarotris*, *Aedes tarshis*, *Aedes fowleri*, *Aedes metallicus*, *Aedes minutus*, *Aedes neoafricanus* and also mosquitoes belonging to *Culex*, *Mansonia* and *Anopheles* species but their significance in Zika fever transmission is unclear [18, 30, 31]. The extrinsic incubation period in the mosquito is found to be up to 10 days [5, 32].

During heavy rains proliferation of the mosquitoes leads to their spread from the forest to nearby villages thus infecting the local inhabitants. Increased human activity in the forest also facilitates the initiation of the urban cycle [18]. Studies have suggested that Zika infections peak towards the end of the rainy season [33].

Reasons for the emergence of Zika virus infection have been speculated. Zhu *et al.* have found genomic changes in the epidemic strain from the pre-epidemic strain, the significance of which needs to be explored [34]. *Aedes aegypti* and *Aedes albopictus* have been shown to be low competent vectors of Zika virus and it is suggested that large number of susceptible population and their close contact with *Aedes* mosquito have contributed to the rapid spread of Zika virus [35]. In addition, factors like globalization, urbanization, climatic changes, increased awareness of Zika virus disease and improved diagnostic capacity have led to increased detection of Zika virus cases [34].

*Aedes aegypti* is a day-biting mosquito and typically rests indoors [36]. It lays eggs in artificial collections of water like domestic water storage including overhead tanks, ground water storage tank and septic tanks as well as rain-filled habitats like used

tires, discarded food and beverage containers and non-household cryptic breeding sites like blocked gutters and storm drains [36-38].

Zika virus disease has not yet been reported in India though the mosquito vector *Aedes aegypti* and *Aedes albopictus* are widely prevalent [39, 40]. Once infection is transmitted, there is a possibility of establishment of Zika virus disease in India [41]. Hence countries like India have to be on the look out to prevent introduction of cases into the country.

#### MODES OF TRANSMISSION

Zika virus is most frequently transmitted to humans by the bite of the female *Aedes aegypti* mosquito which also transmits Dengue and Chikungunya [42]. It can also be transmitted vertically from infected pregnant mothers to their fetuses leading to congenital malformations like microcephaly [7].

Sexual transmission of Zika virus has also been reported. Replicative Zika virus particles were demonstrated in the semen sample of a patient with Zika virus infection and haemospermia [43]. In a study by Barry Atkinson *et al.*, semen samples were positive for Zika virus by rRT-PCR (real time reverse transcriptase polymerase Chain Reaction) up to 62 days after onset of febrile illness [44]. It has also been shown that the viral load in the semen was roughly 100,000 times that of his blood or urine, tested more than 2 weeks after symptom onset, which could facilitate potential sexual transmission of the virus [45]. B.D. Foy *et al.*, have reported a case of an American scientist who acquired Zika fever in Bandafassi in Southeastern Senegal and after returning transmitted it to his wife who had not travelled outside USA during the previous year [46]. As of June 15, 2016, 11 countries have reported person to person transmission of Zika virus, probably via sexual route [13]. The first documented case of female to male transmission of Zika virus infection was reported in United States of America on 15<sup>th</sup> July 2016 [13].

Due to the high rate of asymptomatic infections caused by Zika virus, there is a potential for Zika virus transmission by blood transfusion [47]. Hence blood donation should be deferred from donors returning from areas with an outbreak of Zika virus infection [47]. Presence of infective Zika virus particle in breast milk with substantial viral loads (850000 copies per mL) has been reported [48]. The significance of this finding in transmitting the virus from the infected breast feeding mother to her child needs to be explored. Monkey bite has also been suggested as a potential route of transmission based on the case of an American traveller who developed Zika virus infection 5 days after a monkey bite in Indonesia [5].

#### CLINICAL PRESENTATION

This infection was a neglected tropical disease before 2015 and its natural history is still understudied [45]. The first systematic study of the clinical presentation of Zika virus infection was published by Bancroft, when he inoculated the Eastern Nigerian strain of Zika virus in a human volunteer. The volunteer developed a mild, short-lived febrile illness with headache after 82 hours of inoculation [49]. Clinical features can be indistinguishable from Dengue and Chikungunya making diagnosis difficult in areas where these infections co-exist [50]. Majority (around 80%) of infections are asymptomatic [50]. Incubation period of Zika fever is unknown, but it has been shown that symptoms appear 3–12 days after mosquito bite and resolve within 7 days [51]. The most common symptom seen with Zika virus infection are low grade fever, an often pruritic maculopapular rash that spreads from face to limbs, arthralgia and non-purulent conjunctivitis. Other symptoms include frontal headache, myalgia, retro-orbital pain, peri-articular edema & vomiting [4, 11, 52]. Cervical and retroauricular lymphadenopathy were also frequent findings [51]. Moderate thrombocytopenia has also been occasionally associated with Zika virus infection [53]. Mortality rate with Zika virus is very low [54].

Though Zika fever is a mild self-limiting disease, it has gained importance due to the increasing incidence of neurological complications following Zika fever like Guillain-Barre Syndrome and congenital malformations like microcephaly in infants born to infected mothers. Based on current research, there is scientific consensus that Zika virus is one of the causes of congenital central nervous system malformations and Guillain-Barre Syndrome [13]. The pathogenesis of these two conditions vary, with fetal abnormalities possibly being the result of direct fetal invasion and Guillain-Barre syndrome occurring possibly due to exaggerated autoimmune response [24].

#### Congenital Zika virus infection

An association has been found between Zika virus infection in early pregnancy, especially in the first trimester and risk of development of microcephaly [55]. Neurological involvement has been described following intrauterine infection with other Flaviviruses also like West Nile virus and Chikungunya virus [56]. According to Brazil Ministry of Health, between 22<sup>nd</sup> October 2015 to 9<sup>th</sup> July 2016, a total of 8,451 suspected cases of microcephaly and congenital malformations of central nervous system have been reported in newborns of which 1687 cases were confirmed due to Zika virus in accordance with Brazil's surveillance and response protocol and 3622 cases discarded due to other causes and 3142 remain under investigation [57].

Microcephaly is defined as neonatal head circumference measured 24 hours after birth and within the first week of life, of greater than or equal to 2 Standard Deviations below the mean for gestational age and sex of the infant; with severe microcephaly being defined as head circumference more than 3 Standard Deviations below the mean for gestational age [58, 59]. It is estimated that the risk of microcephaly in the child was about 1% with infection of the mother with Zika virus during the first trimester of pregnancy [56]. The CT and MRI brain imaging features most commonly found in case of congenital Zika virus infection include calcification, cortical hypergyration, ventriculomegaly, enlarged cisterna magna, corpus callosum abnormalities (hypoplasia or hypogenesis), delayed myelination and cerebellum and brainstem hypoplasia suggesting that Zika virus is associated with disruption in brain development [60].

Presence of Zika virus envelope protein and nonstructural protein 5 in brain tissues of newborns with microcephaly indicates that brain is the main target organ of viral replication in the foetus, highlighting a strong neurotropism [61, 62]. Zika virus has also been isolated from the brain of fetus with congenital Zika virus infection providing further evidence for its association with fetal brain damage [23]. In addition, studies have also demonstrated Zika virus genome by Real Time – quantitative Polymerase Chain Reaction (RT-qPCR) and anti-Zika virus IgM antibodies by ELISA in the amniotic fluid of pregnant women whose fetuses had been diagnosed with microcephaly [63]. Zika virus RNA has been identified in the amniotic fluid of women whose fetuses had been found to have microcephaly by prenatal ultrasound [58].

The temporal and spatial relationship between outbreaks of Zika virus disease and increased detection of microcephaly, suggests a presumptive link between these two epidemiological events [55]. This is further substantiated by the fact that Zika virus can directly infect human Neural Progenitor cells (hNPCs) leading to attenuated population growth through virally induced caspase-3 mediated apoptosis and cell-cycle dysregulation [64]. Damage of placental barrier by Zika virus facilitates fetal infections [61].

Ocular examination of children with microcephaly due to Zika virus have shown several abnormalities [65]. Optic nerve findings consists of hypoplasia with double ring sign, pallor and increased cup-to-disk ratio and the macular abnormalities were foveal reflex loss, mild to gross pigment mottling and sharply demarcated circular areas of chorioretinal atrophy [65]. In addition intra-uterine Zika virus infection has also shown to cause hydranencephaly, hydrospetalis and fetal demise [66].

### **GuillainBarre Syndrome (GBS)**

Guillain-Barre syndrome is an acute paralytic neuropathy, preceded by infection or other forms of immune stimulation leading to an aberrant autoimmune response that targets peripheral nerves and their spinal roots [67].

The first case of Guillain-Barresyndrome occurring 7 days after Zika virus infection was reported in French Polynesia in December 2013 [68]. During the outbreak in French Polynesia, the incidence of GBS has escalated 20 times [68]. 42 patients were admitted to the hospital with GBS. 88% of these cases reported having Zika virus symptoms roughly 6 days preceding the onset of neurological symptoms [69]. Serological investigations performed on these 42 patients confirmed that all patients had experienced Zika virus infection [70]. Incidence of GBS has been estimated to be 0.24 per 1000 Zika virus infections during the French Polynesian outbreak [70].

In 2015, Brazil registered 1708 cases of GBS demonstrating a 19% surge in comparison to previous year [71]. Zika virus has been demonstrated by Reverse Transcriptase PCR in urine of patients with GBS, with viremia lasting for more than 15 days after symptom onset [72].

Other neurological complications following Zika virus infection like acute myelitis and meningoencephalitis have also been reported [34, 73].

### **LABORATORY DIAGNOSIS**

Due to the similarity in clinical presentation with Dengue and Chikungunya, laboratory diagnosis is essential for confirming Zika virus infection. A Biosafety level 2 containment is required for handling suspected samples [74, 75].

#### **Nucleic Acid Testing**

Zika virus can be diagnosed in the first week by performing real time Reverse Transcriptase Polymerase Chain Reaction (rRT-PCR) on serum targeting the non-structural protein – 5 genomic region [41, 76, 77]. However, a negative rRT-PCR result does not exclude Zika virus infection, and in such cases serum IgM antibody testing for Zika and Dengue virus infection should be performed [78]. WHO recommends whole blood, serum or urine sample for nucleic acid testing (NAT) [79].

After first week of symptom onset, urine is the ideal sample for PCR for Zika virus as levels of viremia among Zika infected patients are relatively low lasting only 3-5 days. Viremia decreases rapidly after appearance of rash which occurs 2-3 days after disease onset [80-82]. Studies have shown that viral RNA can be detected in urine as early as 4 days after symptom

onset to up to more than 2 weeks, while viral RNA was detectable in plasma up to day 10 after symptom onset [83, 84]. Hence urine samples can be used as an alternative to serum or plasma for detection of Zika virus RNA because of a longer period of RNA detection, higher RNA levels than serum and less invasive sample collection [84].

Detection of Zika virus RNA in saliva has also been reported with a higher viral load than plasma [83, 85]. Though some studies have reported persistent shedding of virus in saliva, it is believed that the use of saliva only improved the ability to detect Zika virus RNA within the first week from symptom onset without increasing the duration of window of detection in contrast to what is reported for urine [85].

In India the Reverse Transcriptase Polymerase Chain Reaction is available in National Institute of Virology, Pune and National Centre for Disease Control, Delhi for testing Zika virus from serum sample during the acute stage of illness [86].

#### **Virus isolation**

Zika virus can be isolated by intracerebral inoculation into newborn mice or isolated in mosquito derived cell lines (AP-61: *Aedes pseudoscutellaris* and C6/36: *Aedes albopictus*) and non-human primate cell lines (VERO cell line and Baby Hamster Kidney cell line) [18]. Viral growth on cell lines can be confirmed by an indirect immunofluorescence assay (IFA)[20]. Though viral isolation is considered as the 'gold standard' for viral diagnosis, it is not the preferred method as it is labor intensive, time consuming and is cumbersome for routine use [20].

#### **Serology**

According to WHO, for patients presenting after 7 days of symptom onset, serology is the preferred method [79]. WHO recommended serological assays include Enzyme Immunoassays (EIAs) and Immunofluorescence assays (IFA) detecting IgM antibodies as well as neutralization assays such as Plaque-Reduction Neutralization Tests (PRNTs) [79]. WHO also recommends testing for Dengue and Chikungunya along with Zika virus due to presence of co-infection in flavivirus endemic areas [79]. This not only increases the cost, but also limits the diagnosis of Zika virus to be performed by ruling out related Flavivirus infections [87].

Serological testing focuses on detecting IgM antibodies in serum or Cerebrospinal fluid using IgM antibody capture Enzyme-Linked Immunosorbent Assay (Zika Mac-ELISA) [78]. Serological assays can be false positive due to cross reacting antibodies to other Flaviviruses like Dengue virus [88]. Studies have shown that cross reactions with Dengue virus IgM assay

can occur in Zika virus infected patients especially if Zika virus is a secondary flavivirus infection. This phenomenon described as 'original antigenic sin' will lead to the erroneous conclusion of Dengue virus infection in a patient with Zika fever due to cross reacting antibodies in sera of patients previously infected with Dengue [80]. This can be differentiated by Plaque Reduction Neutralization testing which provides higher specificity [88]. A four-fold rise in neutralizing antibody titres in the absence of a rise in antibody titre to other flaviviruses is further evidence of recent Zika virus infection, though these results might not discriminate between anti-Zika virus antibodies and cross-reacting antibodies due to secondary flavivirus infections [79]. Hence the Centre for Disease Control and Prevention recommends a more conservative approach to interpret results of Plaque Reduction Neutralization Test (PRNT) [78]. A PRNT using plaque reduction cut-off value of 90% with a titre of  $\geq 10$  against Zika virus and negative PRNTs against other flaviviruses is confirmatory for recent Zika virus infection [78]. There is a strong and urgent need for the development of quality assured, safe, simple, rapid and specific universally available in vitro diagnostic test for Zika virus diagnosis at or near the point of care facility [79].

#### **TREATMENT**

Due to lack of an approved antiviral agent, treatment of Zika fever is symptomatic involving adequate fluid intake, rest, antipyretics like Paracetamol, preventing mosquito bites to hinder further spread to others and in pregnant patients monitoring for birth defects and appropriate counselling [89]. Several drugs have shown antiviral activity against Zika virus like Azathioprine, Bortezomib, Daptomycin, Ivermectin, Mefloquine, Mycophenolic acid, etc [90]. These drugs have to be further evaluated for use in treatment of Zika fever. Drug target sites like Zika virus helicase and RNA-dependent RNA polymerase (NS5) have also been proposed for discovering of new drugs with anti-Zika activity [91, 92].

#### **CONTROL**

There is currently no approved vaccine for the treatment or prevention of Zika virus disease though a few candidate vaccines are being tested [39]. 15 research groups including an Indian firm, Bharath Biotech are in the race for vaccine development [89].

Control of Zika virus disease aims at preventing virus transmission using a comprehensive approach by way of vector surveillance by larval and adult surveys and by integrated management of *Aedes* mosquitoes [37].

#### **Mosquito control**

*Aedes* mosquitoes can breed in extremely small amounts of water and their eggs are very sturdy,

making vector control difficult [93]. Mosquito control involves control of breeding sites and destruction of adult mosquitoes. The mosquito eggs, larvae and pupae population can be controlled by eliminating mosquito breeding sites by community clean-up campaigns, use of larvicides like Temephos, larvivorous fish and other larvivorous aquatic insects, mosquito proofing of overhead tanks, cisterns or underground reservoirs, improved drainage, introducing efficient irrigation practices like weekly flushing, etc. [36, 37]. Endotoxin-producing bacteria, *Bacillus thuringiensis* serotype H-14 (Bt H-14) has been found an effective mosquito control agent [37]. Adult mosquitoes can be controlled by targeted residual spraying applied selectively to areas known to be resting sites for *Aedes* mosquito and space spraying techniques like cold fogging or thermal fogging which targets adult mosquitoes while they are in flight and has no residual effect [36].

Two innovative approaches that have shown considerable promise in the recent years is genetic control of *Aedes aegypti* mosquitoes like RIDL (Release of Insects carrying Dominant Lethal genes) which involves releasing male mosquitoes provided with dietary supplement not present in nature like Tetracyclin which repress the lethal gene activation [10]. Offspring of such mosquitoes do not survive to the adult stage because they do not receive the dietary additive in the wild [10]. The alternative approach is use of endosymbiotic bacteria to prevent arbovirus replicating within the mosquito, for example by releasing *Wolbachia* infected mosquitoes into the wild [10]. Laboratory results have shown that *Wolbachia* infection reduces replication of Dengue virus, Chikungunya virus and Zika virus in *Aedes* mosquito and eliminates or markedly delays appearance of virus in mosquito saliva, thus reducing competence of mosquito to transmit viruses [36].

#### Personal protection

Personal protective measures include application of repellents to exposed skin, wearing clothes that minimizes skin exposure, using window, door screens, safe repellents, avoidance of unprotected sexual activity with a possibly infected partner, using insecticidal mosquito nets when sleeping during the day, avoiding travel to affected areas and avoidance of pregnancy in women residing in affected areas [36, 89, 94]. It has been suggested that men returning from countries with ongoing virus transmission should abstain from sexual activity or use condom for 28 days after return and if infected they should use a condom for 6 months after recovery [95].

#### Community education

Persistent Behavior Change Campaign (BCC) is essential to educate the community about the mode of

transmission, vector control options, availability of services including appropriate treatment, so that timely and appropriate action is taken [37].

#### Surveillance

Integrated surveillance at various levels involving both private and public sector is essential for the prompt detection and control of outbreaks of Zika fever [89].

#### CONCLUSION

Zika fever, once considered a mild self-limiting arboviral disease has emerged as an important public health concern due to increased incidence of congenital malformations and neurological complications like Guillain-Barre Syndrome associated with it. It has also transpired as a disease with pandemic potential. Various factors like globalization, urbanization, climatic changes and large number of susceptible population and their close contact with *Aedes* mosquito has facilitated the rapid spread of this virus [34, 35]. Diagnosis of Zika fever can be confounded due to the presence of cross-reacting antibodies in the sera of patients residing in areas where other flaviviruses are co-circulating [80]. Ongoing active surveillance and vector control measures are essential to curb the menace of Zika virus and to prevent it from becoming a universal health problem.

**Acknowledgements:** The author thanks Dr. Sunitha BU, Dr. Suma Kulkarni and Dr. Priyadarshini D of Shridevi Institute of Medical Sciences and Research Hospital for their critical reading of this article.

#### REFERENCES

1. Dick W.G.A.; Epidemiological notes on some viruses isolated in Uganda (Yellow fever, Rift Valley fever, Bwamba fever, West Nile, Mengo, Semliki forest, Bunyamwera, Ntaya, Uganda S and Zika viruses). *Trans. R. Soc. Trop. Med. Hyg.*, 1953; 47:13-48.
2. Fagbami AH; Zika virus infections in Nigeria: virological and seroepidemiological investigations in oyo state. *J Hyg.* 1979; 83: 213 – 219.
3. Macnamara FN; Zika virus: A report on three cases of human infection during an epidemic of jaundice in Nigeria. *Trans Royal Soc Trop Med Hyg.* 1954; 48(2): 139 – 145.
4. Duffy MR, Chen T-H, Hancock WT, Powers AM, Kool JL, Lanciotti RS et al.; Zika virus outbreak on Yap Island, Federated States of Micronesia. *N Engl J Med.* 2009; 360: 2536 – 43.
5. Hayes EB; Zika virus outside Africa. *Emerg Infect Dis.* 2009; 15(9): 1347 – 1350.
6. Cao-Lormeau V-M, Roche C, Teissier A, Robin E, Berry A-L, Mallet H-P; Zika virus, French Polynesia, South Pacific, 2013. *Emerg Infect Dis.* 2014; 20(6): 1085 – 1086.

7. Besnard M, Lastere S, Teissier A, Cao-Lormeau, Musso D; Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. *Euro Surveill.* 2014; 19(13): pii=20751. Available online at <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20752>.
8. Buathong R, Hermann L, Thaisomboonsuk B, Rutvisuttinunt W, Klungthong C, Chinnawirotpisan P et al.; Detection of Zika virus infection in Thailand, 2012 – 2014. *Am J Trop Med Hyg.* 2015; 93(2): 380 – 383.
9. Musso D, Nilles EJ, Cao-Lormeau; Rapid spread of emerging Zika virus in the Pacific area. *ClinMicrobiol Infect.* 2014; 20(10): 595 – 596.
10. Yakob L, Walker T; Zika virus outbreak in the Americas: the need for novel mosquito control methods. *The Lancet.* 2016; 4: e148-49.
11. Zanoluca C, De Melo CA, Mosimann ALP, Santos GIV, Santos CND; First report of autochthonous transmission of Zika virus in Brazil. *MemInstOswaldo Cruz.* 2015; 110(4): 569-572.
12. World Health Organization. Situation report. Zika virus. Microcephaly. Guillain-Barre Syndrome. 9 June 2016. Available online at: <http://www.who.int/emergencies/zika-virus/situation-report/9-june-2016/en/>.
13. World Health Organization. Zika situation report. 21 July 2016. Zika virus, Microcephaly and Guillain-Barre syndrome. Available online at: <http://www.who.int/emergencies/zika-virus/situation-report/21-july-2016/en/>.
14. Heymann DL, Hodgson A, Sall AA, Freedman DO, Staples JE, Althabe F et al.; Zika virus and microcephaly: why is this situation a PHEIC? *Lancet.* 2016; 387: 719-721.
15. Balkhair A, Al-Maamari K, Alawi FB, Al-Adawi B.; Zika virus: A roar after years of whispering. *Oman Med J.* 2016; 31(2): 87-88.
16. Focosi D, Maggi F, Pistello M.; Zika Virus: Implications for Public Health. *Clin. Infect. Dis.* 2016: 1-7.
17. Pyke AT, Daly MT, Cameron JN, Moore PR, Taylor CT, Hewitson GR, et al.; Imported Zika virus infection from Cook Islands into Australia, 2014. *PLOS Currents Outbreaks.* 2014 June 2. Edition 1. doi: <http://dx.doi.org/10.1371/currents.outbreaks.4635a54dbffba2156fb2fd76dc49f65e>.
18. Slavov SN, Otaguiri KK, Kashima S, Covas DT; Overview of Zika virus (ZIKV) infection in regards to the Brazilian epidemic. *Braz J Med Biol Res.* 2016; 49(5): e5420. doi: <http://dx.doi.org/10.1590/1414-431X20165420>.
19. Lazear HM, Diamond MS; Zika virus: New clinical syndromes and its emergence in the western hemisphere. *J Virol.* 2016; 90: 4864 – 4875. doi: <http://dx.doi.org/10.1128/M00252-16>.
20. Faye O, Faye O, Diallo D, Diallo M, Weidmann M, Sall AA; Quantitative real-time PCR detection of Zika virus and evaluation with field-caught mosquitoes. *Virol J.* 2013; 10: 311.
21. Faria NR, Azevedo RDD, Kraemer MUG, Souza R, Cunha MS, Hill SC, et al.; Zika virus in the Americas: Early epidemiological and genetic findings *Science.* 2016; 352(6283): 345 – 349.
22. Campos GS, Bandeira AC, Sardi SI; Zika virus outbreak, Bahia, Brazil. *Emerg Infect Dis.* 2015; 21(10): 1185 – 1186.
23. Driggers RW, Ho CY, Kornhonen EM, Jaaskelainen AJ, Smura T, Rosenberg A et al; Zika virus infection with prolonged maternal viremia and fetal brain abnormalities. *N Engl J Med.* 2016; 374 (22): 2142 – 2151.
24. Logan IS; Zika – How fast does this virus mutate? *Zool Res.* 2016; 37(2): 110 – 115.
25. Musso D, Gubler DJ; Zika virus. *ClinMicrobiol Rev.* 2016; 29(3): 487-524.
26. Diallo D, Sall AA, Diagne CT, Faye O, Faye O, Ba Y et al; Zika virus emergence in mosquitoes in southeastern Senegal, 2011. *PLOS one.* 2014; 9(10): e109442. doi:10.1371/journal.pone.0109442.
27. Wong PSJ, Li MI, Chong C-S, Ng L-C, Tan C-H; Aedes (Stegomyia) albopictus (Skuse): A potential vector of Zika virus in Singapore. *PLOS Negl Trop Dis.* 2013; 7(8): e2348. doi:10.1371/journal.pntd.0002348.
28. McCrae, Kirya BG; Yellow fever and Zika virus epizootics and enzootics in Uganda. *Trans R Soc Trop Med Hyg.* 1982; 76(4): 552 – 562.
29. Grard G, Caron M, Mombo IM, Nkoghe D, Ondo SM, Jiolle D et al. *PLOS Negl Trop Dis.* 2014; 8(2): e2681. doi:10.1371/journal.pntd.0002681.
30. Haddow AJ, Williams MC, Woodwall JP, Simpson DIH, Goma LKH; Twelve isolation of Zika virus from Aedes (Stegomyia) africanus (Theobald) taken in and above a Uganda forest. *Bull WldHlth Org.* 1964; 31: 57 – 69.
31. Vorou R; Zika virus, vectors, reservoirs, amplifying hosts, and their potential to spread worldwide: what we know and what we should investigate. *Int J Infect Dis.* 2016; 48: 85 – 90.
32. Majumder MS, Cohn E, Fish D, Brownstein JS; Estimating a feasible serial interval range for Zika fever. *Bull WldHlth Org.* E-pub: 9 Feb 2016. doi: <http://dx.doi.org/10.2471/BLT.16.171009>.
33. Olson JG, Ksiazek TG, Suhandiman, Triwibowo; Zika virus, a cause of fever in Central Java, Indonesia. *Trans R Soc Trop Med Hyg.* 1981; 75(3): 389 – 393.
34. Zhu Z, Chan J F-W, Tee K-M, Choi G K-Y, Lau S K-P, Woo P C-Y, et al.; Comparative genomic analysis of pre-epidemic and epidemic Zika virus strains for virological factors potentially associated with the rapidly expanding epidemic. *Emerg*

- Microbes Infect. 2016; 5: e22. doi: <http://dx.doi.org/10.1038/emi.2016.48>.
35. Chouin-Carneiro T, Vega-Rua A, Vazielle M, Yebakima A, Girod R, Goindin D et al.; Differential susceptibilities of *Aedes aegypti* and *Aedes albopictus* from the Americas to Zika virus. *PLOS Negl Trop Dis*. 2016; 10(3): e0004543. doi:10.1371/journal.pntd.0004543.
  36. World Health Organization. Vector control operations framework for Zika virus. Available online at [http://apps.who.int/iris/bitstream/10665/207481/WHO\\_ZIKV\\_VC\\_16.4\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/207481/WHO_ZIKV_VC_16.4_eng.pdf).
  37. Government of India. National Vector Borne Disease Control Programme, Directorate General of Health Services, Ministry of Health & Family Welfare. Guidelines for integrated vector management for control of *Aedes* mosquito. Available online at <http://www.mohfw.nic.in/showfile.php?lid=3706>.
  38. Paploski IAD, Rodrigues MS, Mugabe VA, Kikuti M, Tavares AS, Reis MG et al.; Storm drain as larval development and adult testing sites for *Aedes aegypti* and *Aedes albopictus* in Salvador, Brazil. *Parasites & Vectors*. 2016; 9: 419. doi: 10.1186/s13071-016-1705-0.
  39. Government of India. Ministry of Health and Family welfare. Directorate General of Health Services. Guidelines on Zika virus disease following epidemic in Brazil and other countries of America. Available at <http://www.mohfw.gov.in/showfile.php?lid=3705>.
  40. Kalra NL, Kaul SM, Rastogi RM; Prevalence of *Aedes aegypti* and *Aedes albopictus* vectors of Dengue and Dengue haemorrhagic fever in North, North-East and Central India. *Dengue Bulletin*. 1997; 21: 84 – 92.
  41. Algorithm for Zika virus diagnosis, National Institute of Virology, Pune. Available at <http://www.icmr.nic.in/zika/introduction.pdf>.
  42. Powell JR, Tabachnick WJ; History of domestication and spread of *Aedes aegypti* – A Review. *MemInstOswaldo Cruz*. 2013; 108(Suppl. 1): 11 – 17.
  43. Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau; Potential sexual transmission of Zika virus. *Emerg Infect Dis*. 2015; 21(2): 359-361.
  44. Atkinson B, Hearn P, Afrough B, Lumley S, Carter D, Aarons EL. et al.; Detection of Zika virus in semen. *Emerg Infect Dis*. 2016; 22(5): 940.
  45. Mansuy JM, Dutertre M, Mengelle C, Fourcade C, Marchou B, Delobel P. et al.; Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen? *Lancet Infect Dis*. 2016; (16): 405.
  46. Foy BD, Kobylinski KC, Foy JLC, Blitvich BJ, Rosa AT, Haddock AD et al.; Probable non-vector-borne transmission of Zika virus, Colorado, USA. *Emerg Infect Dis*. 2011; 17(5): 880-82.
  47. Musso D, Nhan T, Robin E, Roche C, Bierlaire D, Zisou K. et al.; Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2014 to February 2014. *Euro Surveill*. 2014; 19(14):pii=20761. Available online :<http://www.erosurveillance.org/ViewArticle.aspx?ArticleId=20761>.
  48. Dupont-Rouzeyrol M, Biron A, O'Connor O, Huguon E, Desloux E; Infectious Zika viral particles in breast milk. *The Lancet*. 2016; 387: 1051. DOI: [http://dx.doi.org/10.1016/S0141-6736\(16\)00624-3](http://dx.doi.org/10.1016/S0141-6736(16)00624-3).
  49. Bearcroft WGC; Zika virus infection experimentally induced in a human volunteer. *Trans Royal Soc Trop Med Hyg*. 1956; 50(5): 442 – 448.
  50. Campos GC, Sardi SI, Sarno M, Brites C.; Zika virus infection, a new public health challenge. *Braz J Infect Dis*. 2016; 20(3): 227-228.
  51. Brasil P, Calvet GA, Siqueira AM, Wakimoto M, de Sequeira PC, Nobre A, et al.; Zika virus outbreak in Rio de Janeiro, Brazil: Clinical characterization, epidemiological and virological aspects. *PLoS Negl Trop Dis*. 2016; 10(4): e0004636. doi: <http://dx.doi.org/10.1371/journal.pntd.0004636>.
  52. Simpson DIH.; Zika virus infection in man. *Trans R Soc Trop Med Hyg*. 1964; 58(4): 335-337.
  53. Karimi O, Goorhuis A, Schinkel J, Codrington J, Vreden SGS, Vermaat JS, et al.; Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection. *The Lancet*. 2016; 387: 939 – 940. doi: [http://dx.doi.org/10.1016/S0140-6736\(16\)00502-X](http://dx.doi.org/10.1016/S0140-6736(16)00502-X).
  54. Dirljikov E, Ryff KR, Torres-Aponte J, Thomas DL, Perez-Padilla J, Munoz-Jordan J, et al.; Update: Ongoing Zika virus transmission – Puerto Rico, November 1, 2015-April 14, 2016. *MMWR. Morb Mortal Wkly Rep* 2016; 65: 451 – 455. doi: <http://dx.doi.org/10.15585/mmwr.mm6517e2>.
  55. de Oliveira WK, Cortez-Escalante J, de Oliveira WTGH, do Carmo GMI, Henriques CMP, Coelho GE, et al.; Increase in reported prevalence of microcephaly in infants born to women living in areas with confirmed Zika virus transmission during the first trimester of pregnancy – Brazil, 2015. *MMWR Morb Mortal Wkly Rep* 2016; 65: 242 – 247. doi: <http://dx.doi.org/10.15585/mmwr.mm6509e2>.
  56. Cauchemez S, Besnard M, Bompard P, Dub T, Guillemette-Artur P, Eyrolle-Guignot D, et al.; Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. *Lancet*. 2016; 387: 2125-32.

57. Pan American Health Organization / World Health Organization. Zika epidemiological update, 14 July 2016. Washington D.C.: PAHO/WHO;2016. Available online at [http://paho.org/hq/index.php?option=com\\_docman&task=doc\\_view&Itemid=270&gid=35403&lang=en](http://paho.org/hq/index.php?option=com_docman&task=doc_view&Itemid=270&gid=35403&lang=en).
58. Schuler-Faccini L, Ribeiro EM, Feitosa IML, Horovitz DDG, Cavalcanti DP, Pessoa A et al.; Possible association between Zika virus and Microcephaly – Brazil, 2015. *MMWR Morb Mort Wkly Rep* 2016;65place\_Holder\_For\_Early\_Release:59-62. DOI: <http://dx.doi.org/10.15585/mmwr.mm6503e2>.
59. World Health Organization. Assessment of infants with microcephaly in the context of Zika virus Interim guidance. Available at [http://apps.who.int/iris/bitstream/10665/204475/1/WHO\\_ZIKV\\_MOC\\_16.3\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/204475/1/WHO_ZIKV_MOC_16.3_eng.pdf).
60. Hazin AN, Poretti A, Martelli CMT, Huisman TA; Computed tomography findings in microcephaly associated with Zika virus. *N Engl J Med*. 2016; 375(22): 2193 – 2195.
61. Noronha LD, Zanluca C, Azevedo MLV, Luz KG, Santos CND; Zika virus damages the human placental barrier and presents marked fetal neurotropism. *MemInstOswaldo Cruz*. 2016; 111(5): 287-293.
62. Martines RB, Bhatnagar J, Keating MK, Silvia-Flannery L, Muehlenbachs A, Gary J et al.; Notes from the field: Evidence of Zika virus infection in Brain and placental tissues from two congenitally infected newborns and two fetal losses – Brazil, 2015. *MMWR Morb Mort Wkly Rep* 2016;65place\_Holder\_For\_Early\_Release:159-160. DOI: <http://dx.doi.org/10.15585/mmwr.mm6506e1>.
63. Calvet G, Aguiar RS, Melo ASO, Sampaio SA, Filippis ID, Fabri A et al.; Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study. *Lancet Infect Dis*. 2016; 16: 653-60.
64. Tang H, Hammack C, Ogden SC, Wen Z, Qian X, Li Y et al.; Zika virus infects human cortical neural progenitors and attenuates their growth. *Cell Stem Cell*. 2016; 18: 587-90.
65. Ventura CV, Maia M, Ventura BV, Linden VVD, Araujo EB, Ramos RC et al.; Ophthalmological findings in infants with microcephaly and presumable intra-uterus Zika virus infection. *Arq Bras Oftalmol*. 2016; 79(1): 1-3.
66. Sarno M, Sacramento GA, Khouri R, Rossario MS, Costa F, Archanjo G. et al.; Zika virus infection and stillbirths: A case of hydropsfetalis, hydranencephaly and fetal demise. *PLOS Negl Trop Dis*. 2016; 10(2): e0004517. doi:10.1371/journal.pntd.0004517.
67. Willison HJ, Jacobs BC, Doorn PAV; Guillain-Barre Syndrome. *The Lancet*. 2016; 388: 717 – 727.
68. Oehler E, Watrin L, Larre P, Leparco-Goffart I, Lastere S, Valour F, et al.; Zika virus infection complicated by Guillain-Barre Syndrome – case report, French Polynesia, December 2013. *EurSurveill*. 2014; 19(9):pii=20720. Available online: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20720>.
69. World Health Organization. Emergencies preparedness, response. Guillain-Barre syndrome – France – French Polynesia. Available online at <http://www.who.int/csr/don/7-march-2016-gbs-french-polynesia/en/>
70. Cao-Lormeau V-M, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, et al.; Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. *The Lancet*. 2016; 387: 1531 – 1539. doi: [http://dx.doi.org/10.1016/S0140-6736\(16\)00562-6](http://dx.doi.org/10.1016/S0140-6736(16)00562-6).
71. World Health Organization. Zika virus microcephaly and Guillain-Barre syndrome. Situation report. 19 February 2016. Available online at [http://apps.who.int/iris/bitstream/10665/204454/1/zikasitrep\\_19Feb2016\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/204454/1/zikasitrep_19Feb2016_eng.pdf?ua=1).
72. Roze B, Najioullah F, Ferge J, Apetse K, Brouste Y, Cesaire R, et al.; on behalf of GBS ZikaWorking Group. Zika virus detection in urine from patients with Guillain-Barre syndrome on Martinique, January 2016. *Euro Surveill*.2016; 21(9):pii=30154. doi: <http://dx.doi.org/10.2807/1560-7917.ES.2016.21.9.3.30154>.
73. Carreaux G, Maquart M, Bedet A, Contou D, Brugieres P, Fourati S, et al.;Zika virus associated with meningoencephalitis. *N Engl J Med*. 2016; 374: 16. doi: <http://dx.doi.org/10.1056/NEJMc1602964>.
74. Centres for Disease Control and Prevention. 2009. Biosafety in Microbiology and biomedical laboratories, 5<sup>th</sup> ed. <http://www.cdc.gov/biosafety/publications/bmb15/BMBL.pdf>.
75. Pan American Health Organization. Zika virus (ZIKV) surveillance in the Americas: Laboratory detection and diagnosis. Algorithm for detecting Zika virus (ZIKV). Available online at [http://www.paho.org/hq/injindex.php?option=com\\_docman&task=doc\\_view&gid=30176&Itemid=270](http://www.paho.org/hq/injindex.php?option=com_docman&task=doc_view&gid=30176&Itemid=270).
76. Centers for disease control and prevention. Diagnostic tests for Zika virus. Available online at <http://www.cdc.gov/zika/hc-providers/types-of-tests.html>
77. Araujo LM, Ferreira MLB, Nascimento OJM; Guillain-Barre Syndrome associated with the Zika

- virus outbreak in Brazil. *ArqNueropsiquiatr.* 2016; 74(3): 253 – 255.
78. Rabe IB, Staples JE, Villanueva J, Hummel KB, Johnson AJ, Rose L et al; Interim guidance for interpretation of Zika virus antibody test results. *MMWR Morb Mortal Wkly Rep* 2016; 65. DOI: <http://dx.doi.org/10.15585/mmwr.mm6521e1>.
79. World Health Organization. Laboratory testing for Zika virus infection. Interim guidance. Available at [http://apps.who.int/iris/bitstream/10665/204671/1/WHO\\_ZIKV\\_LAB\\_16.1\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/204671/1/WHO_ZIKV_LAB_16.1_eng.pdf).
80. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, et al.; Genetic and serological properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. *Emerg Infect Dis.* 2008; 14(8): 1232 – 1239.
81. Moulin E, Selby K, Cherpillod P, Kaiser L, Boillat-Blanco N.; Simultaneous outbreaks of dengue, chikungunya and Zika virus infections: diagnosis challenge in a returning traveler with nonspecific febrile illness. *New Microbe and New Infect.* 2016; 11: 6-7.
82. Gourinat A, O'Connor O, Calvez E, Goarant C, Dupont-Rouzeyrol; Detection of Zika virus in urine. *EmergInfect Dis.* 2015; 21(1): 84-86.
83. Barzon L, Pacenti M, Berto A, Singaglia A, Franchin E, Lavezzo E et. al; Isolation of infectious Zika virus from saliva and prolonged viral RNA shedding in a traveller returning from the Dominican Republic to Italy, January 2016. *Euro Surveill.* 2016; 21(10):pii=30159. DOI: <http://dx.doi.org/10.2807/1560-7917>.
84. Campos RM, Cirne-Santos C, Meira GLS, Santos LLR, Meneses MD, Friedrich J. et al.; Prolonged detection of Zika virus RNA in urine samples during the ongoing Zika virus epidemic in Brazil. *J ClinViro.* 2016; 77: 69-70.
85. Musso D, Roche C, Nhan T, Robin E, Teissier A, Cao-Lormeau V; Detection of Zika virus in saliva. *J ClinViro.* 2015; 68: 53-55.
86. Indian Council of Medical Research. Division of epidemiology & communicable diseases. Background note on Zikavirus. Available at <http://www.icmr.nic.in/zika/background%20note%20on%20zika%20virus.pdf>.
87. Duarte G; Challenges of Zika virus infection in pregnant women. *Rev Bras Ginecol Obstet.* 2016. DOI: <http://dx.doi.org/10.1055/s-0036-1584206>.
88. Hennessey M, Fischer M, Staples JE; Zika virus spreads to New Areas – Region of the Americas, May 2015-January 2016. *MMWR Morb Mortal Wkly Rep* 2016;65place\_Holder\_For\_Early\_Release:55-58. doi: <http://dx.doi.org/10.15585/mmwr.mm6503e1>.
89. Bajpai S, Nadkar MY; Zika virus infection, the recent menace of the Aedes mosquito. *J Assoc Physicians India.* 2016; 64: 42-45.
90. Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R et al; A screen of FDA-approved drugs for inhibitors of Zika virus infection. *Cell Host & Microbe.* 2016; 20: 259 – 270.
91. Tian H, Ji X, yang X, Xie W, Yang K, Chen C; The crystal structure of Zika virus helicase: basis for antiviral drug design. *Protein Cell.* 2016; 7(6): 450 – 454.
92. Eyer L, Nencka R, Huvarova I, Palus M, Alves MJ, Gould EA et al.; Nucleoside inhibitors of Zika virus. *J Infect Dis.* 2016; 214: 707 – 711.
93. Paixao ES, Barreto F, Teixeira MG, Costa MCN, Rodrigues LC; History, epidemiology, and clinical manifestations of Zika: A systematic review. *Am J Public Health.* 2016; 106(4): 606-612.
94. Oladapo OT, Souza JP, De Mucio B, De Leon RGP, Perea W, Gulmezoglu.; WHO interim guidance on pregnancy management in the context of Zika virus infection. *Lancet Glob Health.* 2016; 4: e510-e511.
95. Gulland A; Zika virus is a global public health emergency, declares WHO. *BMJ.* 2016; 353:i657. doi: <http://dx.doi.org/10.1136/bmj.i657>.